Roots Analysis has done a detailed study on Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030, covering various important aspects of the industry and identifying key future growth opportunities
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit this link
Key Market Insights
- In the past few years, over 1,200 trials, enrolling close to 0.2 million patients suffering from a myriad of disease indications, have been registered globally to evaluate peptide-based drugs
- Currently, around 50 companies claim to manufacture peptide-based therapeutics; such players also claim to be capable of providing a variety of additional services to their clients
- The market landscape features the presence of multiple well-established players, most of which claim to operate across all scales of operation, having expertise in more than one method of peptide synthesis and purification
- In order to cater to the growing needs of clients / sponsors, companies have established their presence across different regions; presently, the US, the Netherlands and Switzerland are the hubs for peptide production
- Contract manufacturers are actively investing in expanding / upgrading existing capabilities and capacity; manufacturing peptide drugs was observed to be the focus of majority of recently inked deals in this domain
- The current, installed global manufacturing capacity for peptide therapeutics is estimated to be more than 0.15 million liters
- Peptide API drug developers are anticipated to continue to outsource their manufacturing operations in the mid to long term, resulting in an annualized growth rate of over 11.2% within the contract service market
For more information, please visit https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Peptides
3.2.1. Structural Analysis of Peptides
3.2.2. Type of Classes
3.2.3. Peptide Synthesis
3.2.4. Peptide Modification
3.2.4.1. N-terminal Modification
3.2.4.2. Internal Modification
3.2.4.3. C-terminal Modification
3.2.4.4. Other Modification
3.2.5. Peptide Purification
3.2.5.1. Peptide Purity Guidelines
3.3. Overview of Contract Manufacturing
3.3.1. Need for Outsourcing in the Peptide Industry
3.3.2. Key Considerations for Selecting a CMO Partner
3.3.3. Advantages of Outsourcing Manufacturing Services
3.3.4. Risks and Challenges Associated with Outsourcing Peptide Manufacturing Services
3.4. Future Perspectives
- REGULATORY LANDSCAPE
4.1. Chapter Overview
4.2. Regulatory Scenario: North America
4.2.1. The US Scenario
4.2.1.1. Overview
4.2.1.2. General Guidelines
4.3. Regulatory Scenario: Europe
4.3.1. The European Scenario
4.3.1.1. Overview
4.3.1.2. General Guidelines
4.4. Regulatory Scenario: Asia Pacific
4.4.1. Overview
4.4.2. Australian Scenario
4.4.2.1. General Guidelines
4.4.3. Chinese Scenario
4.4.3.1. General Guidelines
4.4.4. Indian Scenario
4.4.4.1. General Guidelines
4.4.5. Japanese Scenario
4.4.5.1. General Guidelines
4.4.6. South Korean Scenario
4.4.6.1. General Guidelines
4.5. Challenges Associated with Peptide Manufacturing
- COMPETITIVE LANDSCAPE
5.1 Chapter Overview
5.2 Contract Peptide API Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Manufacturing Facilities
5.2.5. Analysis by Scale of Operation
5.2.6. Analysis by Peptide Synthesis Method Used
5.2.7. Analysis by Peptide Modification Services Offered
5.2.8. Analysis by Purification Technology Used
5.2.9. Analysis by Regulatory Accreditations / Certifications
5.3. List of Custom Peptide Manufacturers
- COMPANY PROFILES
6.1 Chapter Overview
6.2. Contract Peptide API Manufacturers Based in North America
6.2.1. AmbioPharm
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Facilities and Capabilities
6.2.1.4. Recent Development and Future Outlook
6.2.2. CPC Scientific
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Facilities and Capabilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Creative Peptides
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Facilities and Capabilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4. CSBio
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Facilities and Capabilities
6.2.4.4. Recent Developments and Future Outlook
6.3. Contract Peptide API Manufacturers Based in Europe
6.3.1. Bachem
6.3.1.1. Recent Developments and Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Facilities and Capabilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2. BCN Peptide
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Facilities and Capabilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Corden Pharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Facilities and Capabilities
6.3.3.4. Recent Developments and Future Outlook
6.3.4. PolyPeptide
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Manufacturing Facilities and Capabilities
6.3.4.4. Recent Developments and Future Outlook
6.3.5. Senn Chemicals
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Manufacturing Facilities and Capabilities
6.3.5.4. Recent Developments and Future Outlook
6.4. Contract Peptide API Manufacturers Based in Asia Pacific
6.4.1. Auspep
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Facilities and Capabilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Chinese Peptide
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Facilities and Capabilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Hybio Pharmaceutical
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Facilities and Capabilities
6.4.3.4. Recent Developments and Future Outlook
6.4.4. Peptide Institute
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Manufacturing Facilities and Capabilities
6.4.4.4. Recent Developments and Future Outlook
6.4.5. ScinoPharm
6.4.5.1. Company Overview
6.4.5.2. Service Portfolio
6.4.5.3. Manufacturing Facilities and Capabilities
6.4.5.4. Recent Developments and Future Outlook
- RECENT DEVELOPMENTS
7.1. Chapter Overview
7.2. Partnerships Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Manufacturing (Deal Specific)
7.3.4. Analysis by Regional Distribution
7.3.4.1. Country-Wise Distribution
7.3.4.2. Intercontinental and Intracontinental Deals
7.4. Expansion Models
7.5. List of Recent Expansions
7.6. Emerging Peptide Synthesis Technologies
7.6.1. Chemo-Enzymatic Peptide Synthesis Technology
7.6.2. Continuous Flow Technology
7.6.3. Green Chemistry
- CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3 Peptide Therapeutics: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Recruitment Status
8.3.3. Analysis by Trial Phase
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Geography
8.3.6. Geographical Analysis by Trial Recruitment Status
8.3.8. Geographical Analysis of Active Trials by Trial Phase
8.4. Peptide Therapeutics: Analysis of Enrolled Patient Population
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Phase
8.4.3. Analysis by Trial Registration Year and Trial Status
8.4.4. Analysis by Therapeutic Area
8.4.5. Analysis by Location of Trial Site
8.4.6. Analysis by Trial Status and Location of Trial Site
8.4.7. Analysis of Active Trials by Trial Phase and Location
8.5. Analysis by Type of Sponsor / Collaborator
8.6. Analysis by Clinical Trial Center
- REGIONAL CAPABILITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Overall Landscape of Contract Peptide API Manufacturers
9.4. Regional Capability Analysis: Contract Peptide API Manufacturers in North America
9.5. Regional Capability Analysis: Contract Peptide API Manufacturers in Europe
9.6. Regional Capability Analysis: Contract Peptide API Manufacturing in Asia Pacific
- DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Peptide API Manufacturing: Overall Annual Demand
10.3.1. Analysis by Geography
- CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Peptide API Manufacturing: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.3.4. Analysis by Company Size and Location of Manufacturing
11.3.5. Analysis by Scape of Operation and Location of Manufacturing Facility
11.4. Concluding Remarks
- MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1. Chapter Overview
12.2. Assumptions and Parameter Definitions
12.2.1. Scenario 1
12.2.2. Scenario 2
12.2.3. Scenario 3
12.2.4. Scenario 4
12.3. Concluding Remarks
- MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology
13.3. Overall Contract Peptide Manufacturing Market, 2020-2030
13.3.1. Contract Peptide Manufacturing Market for Peptide API Manufacturing, 2020- 2030
13.3.2. Contract Peptide Manufacturing Market for Peptide FDF Manufacturing, 2020- 2030
13.4. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.5. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Peptide Synthesis Method Used
13.5.1. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Chemical Synthesis Method Used
13.6. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by End User
13.7. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions
13.7.1. Contract Peptide API Manufacturing Market in North America, 2020-2030
13.7.1.1. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.7.1.2. Contract Peptide API Manufacturing Market in North America,2020-2030: Share of Mid-sized Companies
13.7.1.3. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.7.1.4. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.1.5. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.7.1.6. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods
13.7.1.7. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030
13.7.2.1. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.7.2.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.7.2.4. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.2.5. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.7.2.6. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods
13.7.2.7. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030
13.7.3.1. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
13.7.3.2. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
13.7.3.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
13.7.3.4. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.3.5. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Scale Operations
13.7.3.6. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Chemical Synthesis Methods
13.7.3.7. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Non-Chemical Synthesis Methods
- IMPACT OF THE COVID-19 PANDEMIC ON THE PEPTIDE API CONTRACT MANUFACTURING MARKET
14.1. Chapter Overview
14.2. Current Options and Recuperative Initiatives of Key Players
14.2.1. Bachem
14.2.2. CPC Scientific
14.2.3. Corden Pharma
14.2.4. PolyPeptide
14.2.5. Wuxi AppTec
14.3. Impact on Peptide API Contract Manufacturing Market Opportunity
- SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors
15.7. Concluding Remark
- CONCLUSION
16.1. Chapter Overview
16.2. Key Takeaways
- SURVEY TRANSCRIPT(S)
- APPENDIX 1: TABULATED DATA
- APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry.
The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.
Amongst other elements, the report includes:A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World The report also features detailed transcripts of discussions held with the following experts:Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)Birgit Schwab, Senior Manager Strategic Marketing, Rentschler BiotechnologieChristian Bailly, Director of CDMO, Pierre FabreClaire Otjes, Assistant Marketing Manager, Batavia BiosciencesDavid C Cunningham, Director Corporate Development, Goodwin BiotechnologyDietmar Katinger, Chief Executive Officer, Polymun ScientificDenis Angioletti, Chief Commercial Officer, Cerbios-PharmaJeffrey Hung, Chief Commercial Officer, Vigene BiosciencesKevin Daley, Director Pharmaceuticals, NovasepMark Wright, Site Head, Grangemouth, Piramal HealthcareNicolas Grandchamp, R Leader, GEG TechRaquel Fortunato, Chief Executive Officer, GenIbet BiopharmaceuticalsSebastian Schuck, Head of Business Development, Wacker BiotechStephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth BiotechnologiesTatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactoryTim Oldham, Chief Executive Officer, Cell Therapies To request for sample report - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html Key companies covered in the report3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International For more information please click on the following link:Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Other Recent OfferingsCell Therapy Manufacturing Market (3rd Edition), 2019-2030Antibody Contract Manufacturing Market, 2020-2030China Biopharmaceutical Contract Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysis
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
“Global Streetcar Market 2024” Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2024 is Provided to Determine the Market Potential.
In this report, our team research the global Streetcar market by type, application,
Request a sample of Streetcar Market report @ http://www.arcognizance.com/enquiry-sample/445675
Geographically, global Streetcar market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
